

Industry Insight

GLOBAL GENERICS

March 2009

Cygnus

Business Consulting & Research Pvt.Ltd.

Knowledge Partner for Profitable Growth

4th & 5th Floors, Astral Heights, Road No. 1, Banjara Hills, Hyderabad-500034, India

Tel: +91-40-23430203-05, Fax: +91-40-23430201, E-mail: info@cygnusindia.com

Website: www.cygnusindia.com

Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by **Cygnus Business Consulting & Research Pvt. Ltd.** (Cygnus). While reasonable care has been taken in its preparation, Cygnus makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. The information contained herein may be changed without notice. All information should be considered solely as statements of opinion and Cygnus will not be liable for any loss incurred by users from any use of the publication or contents

SYNOPSIS

Global generics market was valued at US\$106.12 billion in 2008, registering a growth of 12.56% over the previous year, which is five times that of patented drugs. The higher growth rate is attributed to the increasing number of patent expiries and the government measures to popularise the use of generics in different countries to contain the healthcare costs. Cardiovascular (CVS) and Central Nervous System (CNS) were the top two therapeutic segments, accounting for one-third of the total generics market. The US market alone accounted for 41% of the total generics market, growing at a rate of 5.6% in 2008 over the previous year. In Europe, Germany was the largest generics market and in Asia Pacific, the Japanese market grew at 8% over the previous year. Cygnus estimates that the global generics market will sustain a CAGR of 14% during the period, 2008-12. Patent expiries of blockbuster drugs and increasing healthcare expenditure will continue to drive the growth of the industry. The major generic firms will become more dominant with further acquisitions in future.

In view of the rising potential of generics market in the world, Cygnus Business Consulting & Research has come up with an updated version of Global Generics Market report. The report comprises 13 chapters. Global generics market overview with various patent challenges, mergers and acquisitions and regional market overview (North America, Europe and Asia Pacific) along with growth drivers of the industry are discussed to provide a broad global scenario of the market. Globally, the industry faces several challenges, which are discussed in Issues and Challenges chapter. The R&D expenditure of global generics companies has been discussed separately, followed by regulations of the industry. Ten leading industry players are discussed in Major Players chapter, followed by critical success factors. Another important topic i.e. key patent expiries during 2008-12 has been discussed. Outlook of the industry is the last chapter.

This report will be useful to pharma industry experts, global investors and generics companies. Financial institutes offering term loans to generic pharma companies can assess the industry status broadly. Students enrolled in Pharma courses will also be benefited by this report.

No of pages: 129

No of figures: 33

No of tables: 19

CONTENTS

1. EXECUTIVE SUMMARY	11
2. HIGHLIGHTS	14
3. MARKET OVERVIEW	16
3.1 Global generics market	16
3.2 Growth rate comparison	16
3.3 Geographical segmentation	17
3.4 Ethical Vs. OTC generics	17
3.5 Top 20 products in the US.....	18
3.6 Major generic companies	18
4. INDUSTRY TREND	20
4.1 Mergers and Acquisitions	20
4.2 Patent challenges	22
4.3 Regulatory changes.....	22
4.4 New Distribution Models.....	23
4.5 Centralised contracting and increasing role of payers	24
5. MAJOR MARKETS.....	25
5.1 North America	25
5.1.1 The US	25
5.1.2 Canada.....	27
5.2 Europe	28
5.2.1 Germany	28
5.2.2 The UK.....	30
5.2.5 Italy.....	33
5.3 Asia Pacific	34

5.3.1 Japan.....	34
5.3.2 China.....	36
5.3.3 India.....	37
6. GROWTH DRIVERS	42
6.1 Cost advantage	42
6.2 Increasing patent expiries.....	43
6.3 Rising healthcare expenditure	45
6.4 Greater M&A activities.....	46
6.5 Shifting disease pattern.....	47
6.6 Changing age structure of the global population	48
7. ISSUES AND CHALLENGES.....	50
7.1 Authorized generics	50
7.2 Patent extension strategies	51
7.3 Price erosion leads to intense competition	52
7.4 Litigation and legal aspects	54
7.5 Competition from low cost manufacturers	55
7.6 More branded companies in generic competition	55
8. RESEARCH AND DEVELOPMENT	56
8.1 R&D spending by major generic companies	56
8.2 Areas of R&D spend.....	56
9. REGULATIONS.....	58
9.1 Regulatory aspects in the US.....	58
9.2 Regulatory aspects in Europe.....	61
9.3 Regulatory aspects in Japan	63
9.4 International agreements on IPR protection	65
9.4.1 General Agreement on Tariffs and Trade, (GATT).....	65

9.4.2 Trade Related Aspects of Intellectual Property Rights (TRIPS)	66
9.4.3 The Paris Convention for the Protection of Industrial Property (PCPIP)	68
9.4.4 The Patent Co-operation Treaty (PCT)	70
10. MAJOR PLAYERS	73
10.1 Teva Pharmaceutical Industries Ltd.	73
10.1.1 Business Profile	73
10.1.2 Financial Profile.....	73
10.1.3 Key Strategies	74
10.1.4 Outlook	75
10.2 Sandoz.....	77
10.2.1 Business profile.....	77
10.2.2 Financial Profile.....	78
10.2.3 Key Strategy	78
10.2.4 Outlook	79
10.3 Watson Pharmaceuticals	80
10.3.1 Business profile.....	80
10.3.2 Financial Profile.....	80
10.3.3 Key Strategy	81
10.3.4 Outlook	81
10.4 Mylan Inc.....	83
10.4.1 Business profile.....	83
10.4.2 Financial Profile.....	84
10.4.3 Key Strategy	84
10.4.4 Outlook	85
10.5 STADA	86
10.5.1 Business profile.....	86
10.5.2 Financial Profile.....	86

10.5.3 Key Strategy	87
10.5.4 Outlook	88
10.6 Pliva.....	89
10.6.1 Business profile.....	89
10.6.2 Financial Profile.....	89
10.6.3 Key Strategy	90
10.6.4 Outlook	90
10.7 Daiichi Sankyo	91
10.7.1 Business Profile	91
10.7.2 Financial Profile.....	91
10.7.3 Key Strategy	92
10.7.4 Outlook	93
10.8 Cipla Ltd.	94
10.8.1 Business profile.....	94
10.8.2 Financial Profile.....	94
10.8.3 Key Strategy	95
10.8.4 Outlook	95
10.9 Actavis	97
10.9.1 Business Profile	97
10.9.2 Financial Profile.....	97
10.9.3 Key Strategy	97
10.9.4 Outlook	98
10.10 Dr. Reddy's Laboratories Ltd.....	99
10.10.1 Business profile	99
10.10.2 Financial Profile	99
10.10.3 Key Strategy	100
10.10.4 Outlook.....	101

11. CRITICAL SUCCESS FACTORS.....	102
11.1 Biogenerics	102
11.2 Outsourcing.....	103
11.3 Venturing into “difficult to make” generics.....	103
11.4 Mergers and Acquisitions	104
11.5 Investments in R&D.....	104
11.6 Identifying the right patents to challenge	105
11.7 Striking alliances.....	106
12. KEY PATENT EXPIRIES – 2008-12	107
13. OUTLOOK.....	111
ANNEXURE – I	113
ANNEXURE II	118
ANNEXURE III.....	126
ANNEXURE IV	128

LIST OF FIGURES

- Figure 3.1: Global generics market - 2004-08 (US\$bn)
- Figure 3.2: Pharmaceutical market vs Generics (2006-08)
- Figure 3.3: Geographical representation of global generics market – 2008
- Figure 3.4: Ethical vs. OTC generics – 2008
- Figure 3.5: Top generic players by revenue- 2008 (US\$ bn)
- Figure 4.1: M&A in global generics market - 2006-08 (US\$ bn)
- Figure 4.2: Number of Para IV filings (2006-08)
- Figure 5.1: US generics market (2004-08)
- Figure 5.2: Growth of Generic prescriptions (2002-07)
- Figure 5.3: Canada generics market (2004-08)
- Figure 5.4: Germany generics market (2004-08)
- Figure 5.5: UK generics market (2004-08)
- Figure 5.6: France generics market (2004-08)
- Figure 5.7: Spain generics market (2004-08)
- Figure 5.8: Italy generics market (2004-08)
- Figure 5.9: Japan generics market (2004-08)
- Figure 5.10: China generics market (2004-08)
- Figure 5.11: India generics market (2004-08)
- Figure 5.12: DMF filings (global vs India)
- Figure 5.13: Country wise DMF filings (2000-08)
- Figure 5.14: Indian ANDA approvals % of total Approvals (2001- 08)
- Figure 5.15: ANDA approvals received by Indian Players (2001-08)
- Figure 6.1: Patent expiries by value (2008-12)
- Figure 6.2: Healthcare expenditure as a % of GDP (2002-06)
- Figure 6.3: Global DALYs by disease - (2000-30)
- Figure 6.4: Percentage of population aged 55 & above as a percentage to the total population (2008-2025)
- Figure 7.1: Authorized generic launches (1999-02 to 2008)
- Figure 7.2: Generics pricing - The market scenario
- Figure 8.1: Top generic players by R&D spend- 2008
- Figure 8.2: Areas of R&D spend by generic firms
- Figure 9.1: Generic drug approval procedure in the US

Figure 11.1: R&D expenditure as a percentage of sales – 2008

Figure 13.1: Global generics market (2008-12)

LIST OF TABLES

- Table 3.1: Top 20 products in world's largest generics market by prescription
- Table 4.1: Key M&A in global generics industry – 2008
- Table 4.2: Key M&A in global generics industry – 2007
- Table 4.3: Key M&A in global generics industry – 2006
- Table 5.1: Top generic companies in the US based on generation of prescriptions during 2005-07(in million)
- Table 5.2: Top 10 generic companies as per retail prescriptions (MAT June 2008)
- Table 5.3: Key M&A by Indian Players in Generics
- Table 5.4: Top 5 players in India (MAT November'08)
- Table 6.1: Cost Comparison of 20 Branded Drugs and their Generic Counterparts
- Table 6.2: Drug Patent Expiries (2008-09)
- Table 7.1 List of authorized generics launched in the past
- Table 7.2: Companies extending patent exclusivity
- Table 11.1: Patent expiration of biological products in US Market
- Table 11.2: Top 10 companies by number of patent challenges
- Table 12.1: Drug Patent Expiries (2008)
- Table 12.2: Drug Patent Expiries-2009
- Table 12.3: Drug Patent Expiries-2010
- Table 12.4: Drug Patent Expiries-2011
- Table 12.5: Drug Patent Expiries-2012